Poland· PL-100485230

Camzyos

A mavacamten product containing mavacamtenum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 15 of our 19 countries.

ATC C01EB24

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCamzyosATCC01EB24REGISTER NO.PL-100485230PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Mavacamten is registered in 15 of 19 countries.

Countries holding a registration under ATC C01EB24 (mavacamten), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Mavacamten · ATC C01EB24

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mavacamten costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mavacamten · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$118.52
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Mavacamtenum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
C01EB24
ATC class
Mavacamten
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    08027950800759
  • gtin
    04150180304217

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mavacamten in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mavacamten products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Camzyos
  • Liechtenstein · Camzyos
  • Norway · Camzyos

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c54a4ed0-6d69-47b7-b32b-246b7758ce58
GET /v1/drugs/c54a4ed0-6d69-47b7-b32b-246b7758ce58?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "15 mg",
  "packaging": "08027950800759 ¦ Rpz ¦ EU/1/23/1716/008 ¦ 150606\n28 kaps.\n¦ UR/Z/4c/127/23 - 04150180304217\nRpz ¦ EU/1/23/1716/007 ¦ 150607\n14 kaps.\nRpz ¦ EU/1/23/1716/012 ¦ 159238\n98 kaps.",
  "substance": "Mavacamtenum 15 mg",
  "common_name": "Mavacamtenum",
  "pl_product_id": "100485230",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about mavacamten.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.